Table 3 Relative hazards of Fib-4 elevation >1.45 from fitting a Cox regression model
Crude and adjusted relative hazards of developing Fib>1.45 | ||||||
|---|---|---|---|---|---|---|
Biomarker | Crude RH (95% CI) | p-value | Adjusted*RH (95% CI) | p-value | Adjusted**RH (95% CI) | p-value |
CD8CD38+DR+, % | ||||||
<=48% | 1.0 | 1.0 | 1.0 | |||
>48% | 5.27 (0.59, 47.23) | 0.137 | 4.62 (0.47, 45.35) | 0.189 | 5.34 (0.31, 92.47) | 0.250 |
not measured | 2.82 (0.37, 21.58) | 0.318 | 2.88 (0.35, 23.80) | 0.327 | 1.71 (0.19, 15.66) | 0.636 |
IL-6, pg/ml | ||||||
<=1.1 | 1.0 | 1.0 | 1.0 | |||
>1.1 | 1.67 (0.59, 4.68) | 0.333 | 1.62 (0.52, 5.05) | 0.403 | 1.24 (0.34, 4.58) | 0.747 |
not measured | 0.71 (0.18, 2.84) | 0.627 | 0.56 (0.13, 2.46) | 0.443 | § | 0.992 |
LPS, pg/ml | ||||||
<=126 | 1.0 | 1.0 | 1.0 | |||
>126 | 0.41 (0.11, 1.60) | 0.200 | 0.36 (0.07, 1.78) | 0.211 | 0.53 (0.08, 3.33) | 0.497 |
not measured | 0.53 (0.19, 1.46) | 0.217 | 0.64 (0.21, 1.96) | 0.431 | 0.71 (0.13, 3.89) | 0.697 |
sCD14, mg/ml | ||||||
<=3.6 | 1.0 | 1.0 | 1.0 | |||
>3.6 | 0.99 (0.36, 2.74) | 0.987 | 0.46 (0.14, 1.53) | 0.206 | 0.20 (0.04, 0.90) | 0.036 |
not measured | 0.69 (0.18, 2.61) | 0.582 | 0.33 (0.08, 1.46) | 0.145 | § | 0.992 |
TNF-alfa, pg/ml | ||||||
<=2.3 | 1.0 | 1.0 | 1.0 | |||
>2.3 | 8.37 (1.90, 36.87) | 0.005 | 15.17 (2.72, 84.76) | 0.002 | 13.05 (2.43, 70.07) | 0.003 |
not measured | 1.70 (0.24, 12.11) | 0.596 | 1.53 (0.17, 13.71) | 0.702 | 0.29 (0.01, 10.81) | 0.503 |